GSK Plc, IDRx
GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour. In a new white paper from the World Without Disease ...
PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with well ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...
GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...
GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback